DPP4 and type 2 diabetes mellitus: SGLT2 inhibitor use provided significant benefits for all-cause and cardiovascular-related mortality and morbidity in patients with type 2 diabetes, compared with both placebo and other OADs such as sulfonylureas, TZD, and DPP4 inhibitors.